 MINNEAPOLIS, July 27, 2021 PRNewswire -- Bio-Techne Corporation NASDAQ: TECH today announced the expansion of the Advanced Cell Diagnostics ACD, a Bio-Techne brand, RNAscope in situ hybridization technology portfolio with the release of new RNAscope HiPlex V2 assay for formalin-fixed paraffin-embedded FFPE and fixed and fresh frozen samples for up to 12 targets. RNAscope is a proven and well characterized technology, with over 4400 peer reviewed publications. 